Remogliflozin etabonate: A novel SGLT2 inhibitor for treatment of diabetes mellitus

Expert Opinion on Investigational Drugs

Volumn 24, Issue 10, 2015, Pages 1381-1387

  Mikhail, Nasser ^a,b  

^a OLIVE VIEW UCLA MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

efficacy; remogliflozin etabonate; safety; SGLT2 inhibitor; type 1 diabetes; type 2 diabetes

Indexed keywords

CYTOCHROME P450; GLUCOSE; HEMOGLOBIN A1C; LIPID; METFORMIN; PIOGLITAZONE; PLACEBO; REMOGLIFLOZIN ETABONATE; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; GLUCOSIDE; GLYCOSYLATED HEMOGLOBIN; PRODRUG; PYRAZOLE DERIVATIVE; SODIUM GLUCOSE COTRANSPORTER 2;

AREA UNDER THE CURVE; ARTICLE; BLOOD PRESSURE; BODY WEIGHT; CLINICAL TRIAL (TOPIC); DIZZINESS; DRUG EFFICACY; DRUG HALF LIFE; DRUG INTERACTION; DRUG METABOLISM; DRUG SAFETY; DRUG WITHDRAWAL; GENITAL FUNGAL INFECTION; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; LIPID BLOOD LEVEL; MAXIMUM PLASMA CONCENTRATION; MYCOSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); RISK; URINARY TRACT INFECTION; WEIGHT REDUCTION; ANTAGONISTS AND INHIBITORS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; METABOLISM; PATHOPHYSIOLOGY;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DRUG INTERACTIONS; GLUCOSIDES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; PRODRUGS; PYRAZOLES; SODIUM-GLUCOSE TRANSPORTER 2;

EID: 84941600467     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2015.1061501     Document Type: Article

References (25)

1. Wright EM, Loo DDF, Hirayama BA. Biology of human sodium glucose transporters. Physiol Rev 2011; 91: 733-94
2. Taylor SR, Harris KB. The clinical efficacy and safety of sodium glucose cotransporter-2 inhibitors in adults with type 2 diabetes mellitus. Pharmacotherapy 2013; 33: 984-99
3. Gerich JE. Role of the kidney in normal glucose homeostasis and in the hyperglycemia of diabetes mellitus: therapeutic implications. Diabetic Med 2010; 27: 136-42
4. Invokana (canagliflozin). Prescribing information. Janssen Ortho. LLC; Gurabo, PR 00778: 2013
5. Farxiga (Dapagliflozin). Prescribing information. Bristol-Myers. Squibb Company; Princeton, NJ, USA: 2014
6. Jardiance (Empagliflozin). Prescribing information. Boehringer. Ingelheim Pharmaceuticals, Inc; Ridgefield, CT, 06877 USA: 2014
7. Fujimori Y, Katsuno K, et al. Remogliflozin etabonate, in a novel category of selective low-affinity sodium glucose cotransporter (SGLT2) inhibitors, exhibits antibdiabetic efficacy in rodent models. J Pharmacol Exp Ther 2008; 327: 268-76
8. Sykes AP, Kemp GL, Dobbins R, et al. Randomized efficacy and safety trial of once-daily remogliflozin etabonate for the treatment of type 2 diabetes. Diabetes Obes Metab 2014; 98-98: 101
9. Sykes AP, OConnor-Semmes R, Dobbins R, et al. Randomized trial showing efficacy and safety of twice-daily remogliflozin etabonate for the treatment of type 2 diabetes. Diabetes Obes Metab 2015; 17: 94-7
10. Sigafoos JF, Bowers GD, Castellino S, et al. Assessment of the drug interaction risk for remogliflozin etabonate, a sodium-dependent glucose cotransporter-2 inhibitor: Evidence from in vitro, human mass balance, and ketoconazole interaction studies. Drug Metab Dispos 2012; 40: 2090-101
11. Hussey EK, Kapur A, OConnor-Semmes R, et al. Safety, pharmacokinetics and pharmacodynamics of remogliflozin etabonate, a novel SGLT2 inhibitor, and metformin when co-administered in subjects with type 2 diabetes mellitus. BMC Pharmacol Toxicol 2013; 14: 25
12. Dobbins RL, OConnor-Semmes R, Kapur A, et al. Remogliflozin etabonate, a selective inhibitor of the sodium-dependent transporter 2 reduces serum glucose in type 2 diabetes mellitus patients. Diabetes Obes Metab 2012; 14: 15-22
13. Kapur A, OConnor-Semmes R, Hussey EK, et al. First dose-escalation study with remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2 (SGLT2), in healthy subjects and in subjects with type 2 diabetes mellitus. BMC Pharmacol Toxicol 2013; 14: 26
14. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and European Association for the Study of Diabetes. Diab Care 2015; 38: 140-9
15. Mikhail N. Place of sodium-glucose type 2 co-transporters inhibitors in treatment of type 2 diabetes. World J Diab 2014; 5 (6): 854-9
16. Mikhail N. Use of sodium-glucose cotransporter type 2 inhibitors in older adults with type 2 diabetes mellitus. South Med J 2015; 108: 1-6
17. Mudallar S, Armostrong DA, Mavian AA, et al. Remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2, improves serum glucose profiles in type 1 diabetes. Diab Care 2012; 35: 2198-200
18. Perkins BA, Cherney DZI, Partridge H, et al. Sodium-glucose cotransporter 2 inhibition and glycemic control in types 1 diabetes: results of an 8-week open-label proof-of-concept trial. Diab Care 2015; 37: 1480-3
19. Bolinger J, Ljunggren O, Kulberg J, et al. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab 2012; 97: 1020-31
20. Cefalu WT, Leiter LA, Yoon KH, et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet 2013; 382: 941-50
21. Baker WL, Smyth LR, Riche DM, et al. Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: A systemic review and meta-analysis. J Am Society Hypertension 2014; 8: 262-75
22. Yale JF, Bakris G, Cariou B, et al. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab 2014; 16: 1016-27
23. Zanoli L, Granata A, Lentini P, et al. Sodium-glucose linked transporter-2 inhibitors in chronic kidney disease. Scientific World J 2015. [Epub ahead of print]
24. Scheen AJ. Phramacokinetics, pharmacodynamics and clinical use SGLT2 inhibitors in patients with type 2 diabetes mellitus and chronic kidney disease. Clin Pharmacokinet 2015. [. Epub ahead of print]
25. OConnor-Semmes R, Walker S, Kapur A, et al. Pharmacokinetics and pharmacodynamics of the SGLT2 inhibitor remogliflozin etabonate in subjects with mild to moderate renal impairment. Drug Metab Dispos 2015; 43: 1077-83